The development of an effective HIV-1 vaccine has been hampered by the rapid rate of mutation and geneticvariation throughout the viral genome, especially the env gene. In this proposal, we seek to analyze theevolution of HIV clade C env genes in children that were perinatally infected. In parallel, we will analyze theevolution of env genes in rhesus monkeys infected with SHIV strains encoding the corresponding HIV cladeC env genes. We hypothesize that the molecular evolution of env genes in the two different species willfollow similar patterns. Together with Core A, we will generate new SHIV strains that encode env genesfrom HIV clade C-infected Zambian infants with rapid HIV disease progression. We hypothesize that Env isa determinant for pathogenicity, which will be mirrored in the corresponding SHIV strains in macaques. Theoverall objective of Project 1 is to determine whether infection of non-human primates by SHIV and theresultant molecular evolution of env therein, is a suitable model for studying HIV-1 evolution in humans.Our immediate goal is to longitudinally isolate samples from perinatally infected infants and to characterizethe patterns and within-host diversification of clade C env genes. Using nucleotide sequence data from viralisolates obtained in parallel from infected humans and macaques, we will test several hypotheses regardingthe relationships among genetic diversity, disease progression, and clinical phenotypes. This proposal willmake use of an ongoing research project to study perinatal transmission of HIV and other viruses inmother/infant pairs (MIPs) from Zambia.
The Specific Aims are:1) To characterize changes in Env proteins of HIV-1 clade C isolated from infants at different time points inthe disease course, and correlate these changes to disease progression.2) To characterize Env proteins of SHIV clade C isolated longitudinally over the disease course in infectedanimals, and correlate these changes to disease progression in both the animals and the patients.3) To characterize the biological properties of Env proteins of viruses obtained from the paired patients andmacaques with time, and correlate these changes to disease progression.This study will provide important predictive information about the evolution of HIV clade C by correlatingpatterns of env evolution with pathogenesis and disease progression. This study will also lead to a betterunderstanding of the host-virus interaction during the disease course and will provide useful information fordesigning vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
2P01AI048240-06A1
Application #
7294563
Study Section
Special Emphasis Panel (ZAI1-MPM-A (J1))
Project Start
2007-01-01
Project End
2012-07-31
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
6
Fiscal Year
2007
Total Cost
$319,306
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Tokatlian, Talar; Kulp, Daniel W; Mutafyan, Andrew A et al. (2018) Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. Sci Rep 8:16527
Ruprecht, Ruth M; Lakhashe, Samir K (2017) Antibody-mediated immune exclusion of HIV. Curr Opin HIV AIDS 12:222-228
Ruprecht, Ruth M (2017) Anti-HIV Passive Immunization: New Weapons in the Arsenal. Trends Microbiol 25:954-956
Schneider, Jeffrey R; Carias, Ann M; Bastian, Arangaserry R et al. (2017) Long-term direct visualization of passively transferred fluorophore-conjugated antibodies. J Immunol Methods 450:66-72
Kulkarni, Viraj; Ruprecht, Ruth M (2017) Mucosal IgA Responses: Damaged in Established HIV Infection-Yet, Effective Weapon against HIV Transmission. Front Immunol 8:1581
Sholukh, Anton M; Watkins, Jennifer D; Vyas, Hemant K et al. (2015) Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine 33:2086-95
Zhou, Mingkui; Ruprecht, Ruth M (2014) Are anti-HIV IgAs good guys or bad guys? Retrovirology 11:109
Sholukh, Anton M; Byrareddy, Siddappa N; Shanmuganathan, Vivekanandan et al. (2014) Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology 11:8
Lakhashe, Samir K; Byrareddy, Siddappa N; Zhou, Mingkui et al. (2014) Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine 32:6527-36
Bachler, Barbara C; Humbert, Michael; Lakhashe, Samir K et al. (2013) Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia. Retrovirology 10:63

Showing the most recent 10 out of 77 publications